Securities code: 600513 securities abbreviation: Jiangsu Lianhuan Pharmaceutical Co.Ltd(600513) Announcement No.: 2022-003 Jiangsu Lianhuan Pharmaceutical Co.Ltd(600513)
Announcement of resolutions of the second extraordinary meeting of the eighth board of supervisors
Special tips:
The board of supervisors and all supervisors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents. 1、 Convening and holding of the meeting
The second interim meeting of the eighth board of supervisors of Jiangsu Lianhuan Pharmaceutical Co.Ltd(600513) (hereinafter referred to as “the company”) was held in the conference room of the company’s headquarters on January 21, 2022. The notice of this meeting was notified to all supervisors by e-mail on January 12, 2022. The meeting was presided over by Mr. Yu Baochang, chairman of the board of supervisors. There were 3 supervisors who should be present and 3 actually present. The meeting complies with the provisions of the company law and the articles of association. 2、 Resolution content and voting
The supervisors attending the meeting carefully considered the following proposals and unanimously adopted the following resolutions by show of hands: 1. The proposal on adjusting the repurchase price of restricted shares was considered and adopted
According to the provisions of the company’s 2019 restricted stock incentive plan (Draft) and the annual equity distribution in 2019 and 2020, it is agreed to adjust the restricted stock repurchase price, and the adjusted restricted stock repurchase price is 3.98 yuan / share.
(voting: 3 in favor, 0 against and 0 abstention)
2. The proposal on the unfulfilled conditions for lifting the restrictions on sales in the first lifting period of the company’s restricted stock incentive plan in 2019 and the repurchase and cancellation of some restricted shares was reviewed and approved
After deliberation, the board of supervisors held that: in view of the performance assessment target of the first lifting of the restriction period of the company’s restricted stock incentive plan in 2019, the growth rate of net profit in 2020 compared with 2018 is lower than the 75th percentile of the benchmark enterprise, and the conditions for lifting the restriction in the first lifting period of the restricted stock incentive plan in 2019 are not met, according to the company’s restricted stock incentive plan in 2019 (Draft) According to the administrative measures for the assessment of the implementation of the company’s restricted stock incentive plan in 2019, the Company repurchased and cancelled 844696 restricted shares of 14 incentive objects that did not meet the conditions for lifting the restrictions in the first lifting period. The above procedures are legal and comply with the measures for the administration of equity incentive of listed companies, the company’s 2019 restricted stock incentive plan (Draft) and other relevant provisions. There is no situation that damages the interests of the company and all shareholders and will not have a material impact on the company’s financial status and operating results. The board of supervisors agrees that the company shall repurchase and cancel some restricted shares that have not met the incentive conditions in accordance with relevant procedures.
(voting: 3 in favor, 0 against and 0 abstention)
3. The proposal on Revising the administrative measures for the implementation and assessment of Jiangsu Lianhuan Pharmaceutical Co.Ltd(600513) 2019 restricted stock incentive plan was considered and adopted
After deliberation, the board of supervisors held that the company’s adjustment to the second and third assessment years of lifting the restriction period of the restricted stock incentive plan in 2019 met the relevant provisions, and the adjustment basis was sufficient and reasonable. It is conducive to fully mobilize the enthusiasm of operation and management personnel, establish and improve the long-term incentive mechanism of the company, and is conducive to the sustainable development of the company. There is no situation that damages the interests of the company and all shareholders, and will not have a substantive impact on the financial status and operating results of the company. The board of supervisors agreed to the company’s adjustment of the second and third assessment years for the lifting of the restricted stock incentive plan in 2019 and the revision of the management measures for the assessment of the implementation of the company’s restricted stock incentive plan in 2019.
(voting: 3 in favor, 0 against and 0 abstention)
4. The proposal on adjusting the benchmarking enterprises of the company’s 2019 restricted stock incentive plan was reviewed and approved. After deliberation, the board of supervisors held that the company’s adjustment of the benchmarking enterprises of the company’s 2019 restricted stock incentive plan was in line with the company’s 2019 restricted stock incentive plan (Draft) and other relevant provisions, and the adjustment basis was sufficient and reasonable to ensure the comparability of the benchmarking enterprises, It maintains a certain sample size, which is conducive to the sustainable development of the company, does not damage the interests of the company and all shareholders, and will not have a substantive impact on the company’s financial status and operating results. The board of supervisors agrees that the company will adjust the target enterprises of the 2019 restricted stock incentive plan.
(voting: 3 in favor, 0 against and 0 abstention)
5. The proposal on Revising the restricted stock incentive plan (Draft) and its summary for Jiangsu Lianhuan Pharmaceutical Co.Ltd(600513) 2019 was deliberated and adopted
After deliberation, the board of supervisors believes that the company’s adjustment to the second and third assessment years of lifting the restriction on sales period of the restricted stock incentive plan in 2019 and the benchmark enterprises comply with relevant regulations, which is conducive to fully mobilize the enthusiasm of operation and management personnel, establish and improve the company’s long-term incentive mechanism, and is conducive to the sustainable development of the company, There is no situation that damages the interests of the company and all shareholders and will not have a material impact on the company’s financial status and operating results. The board of supervisors agreed to the company’s revision of the company’s 2019 restricted stock incentive plan (Draft) and its summary.
(voting: 3 in favor, 0 against and 0 abstention)
It is hereby announced.
Jiangsu Lianhuan Pharmaceutical Co.Ltd(600513) board of supervisors January 22, 2022
